• Mayuri Anil Patil

Targeted cancer therapies have revolutionized oncology by providing precise treatment options that specifically target molecular pathways involved in cancer progression. Because of its important influence on tumour growth, proliferation, and survival, the Epidermal Growth Factor Receptor (EGFR) has become a crucial target for the treatment among these pathways. However, existing EGFR inhibitors face limitations such as acquired resistance and off-target effects, creating a need for innovative approaches. Heterocyclic molecules, known for their structural diversity and favourable pharmacological properties, have demonstrated immense potential as EGFR inhibitors. These compounds offer enhanced specificity, reduced toxicity, and improved efficacy against EGFR mutations. Recent advances in computational drug design and synthetic strategies have further facilitated the development of novel heterocyclic EGFR inhibitors. This review highlights the therapeutic relevance of heterocyclic compounds, their mechanisms of action, and their contributions to overcoming resistance mechanisms in EGFR-targeted therapies. Future directions for designing next-generation inhibitors and their integration into combination therapies are also discussed, accessing up the possibilities for more resilient and improved cancer treatments.

EGFR inhibitors, heterocyclic molecules, targeted cancer therapies, tyrosine kinase inhibitors, drug resistance, molecular docking

"Advancing Targeted Cancer Therapies: The Emerging Role of Heterocyclic Molecules as Potent EGFR Inhibitors", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.12, Issue 9, page no.c562-c585, September-2025, Available :http://www.jetir.org/papers/JETIR2509265.pdf

"Advancing Targeted Cancer Therapies: The Emerging Role of Heterocyclic Molecules as Potent EGFR Inhibitors", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.12, Issue 9, page no. ppc562-c585, September-2025, Available at : http://www.jetir.org/papers/JETIR2509265.pdf